Main content

    Liver Cancer
    (Hepatoma / Hepatocellular Carcinoma / HCC)

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Second Line Treatment

    Second Line Treatment

    Title: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Following First-Line Therapy With Sorafenib
    Description: The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein
    Investigator: Ari Baron, MD
    Eligibility: Subjects 18 y/o and older, with a diagnosis of HCC based on histopathologic findings, or a diagnosis of cirrhosis and a tumor with classical HCC imaging characteristics
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study Lilly JVDE

    Title: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
    Description: Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)
    Investigator: Ari Baron, MD
    Eligibility: Subjects 18 y/o and older, who have a Histological or cytological diagnosis of HCC
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study Exelixis:XL184-309

    Title: A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)
    Description: This is a study of pembrolizumab (MK-3475) in participants with previously systemically treated advanced hepatocellular carcinoma (HCC)
    Investigator: Ari Baron, MD
    Eligibility: Subjects 18 y/o and older, with an HCC diagnosis confirmed by radiology, histology or cytology (fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible)
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study Merck MK3475-240

    • updated April 2017

    Back to top